The pharmacodynamic properties of azithromycin in a kinetics-of-kill model and implications for bacterial conjunctivitis treatment

Advances in Therapy

Volumn 25, Issue 3, 2008, Pages 208-217

  Dorfman, Mark S ^a   Wagner, Rudolph S ^b   Jamison, Tiffany ^c   Bell, Belinda ^c   Stroman, David W ^c  

^a Eye Surgery Associates   (United States)

^b Children's Eye Care Center of New Jersey   (United States)

^c ALCON RESEARCH LTD   (United States)

Author keywords

Azithromycin; Bactericidal; Bacteriostatic; Concentration dependent; Conjunctivitis; Time dependent

Indexed keywords

AZITHROMYCIN; ERYTHROMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONJUNCTIVITIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; HAEMOPHILUS INFLUENZAE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CONJUNCTIVITIS, BACTERIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROMYCIN; HAEMOPHILUS INFLUENZAE; HUMANS; KINETICS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 59249101295     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-008-0034-x     Document Type: Article

References (20)

1. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis. 2004;38:864-870.
2. Peterson LR. Shanholtzer CJ. Tests for bactericidal effects of antimicrobial agents: Technical performance and clinical relevance. Clin Microb Rev. 1992;5:420-432.
3. Wispelway B. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Infect Dis. 2005;41:S127-S135.
4. Shah PM, Junghanns W, Stille W. Bactericidal dose-activity relationships with E. coli, K. pneumoniae and Staph. aureus [in German]. Dtsch Med Wochenschr. 1976;101:325-328.
5. Mueller M, de la Peña A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: Kill curves versus MIC. Antimicrob Agents Chemo. 2004;48:369-377.
6. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-10.
7. Carbon C. Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. Clin Infect Dis. 1998;27:28-32.
8. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrob Agents Chemo. 1987;31:1939-1947.
9. Fernandes PB, Bailer R, Swanson R, et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemo. 1986;30:865-873.
10. Clinical and Laboratory Standards Institute. M7-A7 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Seventh Edition. Wayne, PA: CLSI; 2006;26.
11. Friedlaender MH, Protzko E. Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy. Clin Ophthalmol. 2007;1:3-10.
12. Si EC, Bowman LM, Roy SD. Ocular bioavailability and systemic levels of an ophthalmic formulation of azithromycin, ISV-401. Invest Ophthalmol Vis Sci. 2003;44. Abstract 1461.
13. Stratton CW. Dead bugs don't mutate: Susceptibility issues in the emergence of bacterial resistance. Emerging Infect Dis. 2003;9:10-16.
14. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: New data from the Alexander Project. J Antimicrob Chem. 2000;46(suppl T1):3-9.
15. Gay K, Baughman W, Miller Y, et al. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: A 6-year population-based assessment. J Infect Dis. 2000;182:1417-1424.
16. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chem. 2001;47:129-140.
17. Ohnsman C, Ritterband D, O'Brien T, Girgis D, Kaba A. Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis. Curr Med Res Opin. 2007;23:2241-2249.
18. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: A randomised, doubleblind, placebo-controlled study. Lancet. 2007;369:482-490.
19. Burton MJ, Frick KD, Bailey RL, Boman RJ. Azithromycin for the treatment and control of trachoma. Expert Opin Pharm. 2002;3:113-120.
20. Chern KC, Shrestha SK, Cavallos V, et al. Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. Br J Ophthalmol. 1999;83:1332-1335.